REESE DAVID M 4

What Happened
David M. Reese, Executive Vice President & Chief Technology Officer of Amgen, disposed of 1,433 shares of AMGN on May 2, 2026 to satisfy tax withholding obligations. The disposals were in two lots — 746 shares and 687 shares — at $329.82 per share, for total proceeds of approximately $472,632. These disposals are reported as "Payment of exercise price or tax liability (F)," i.e., shares surrendered to cover taxes rather than open-market selling for investment purposes.

Key Details

• Transaction date: May 2, 2026
• Lots: 746 shares @ $329.82 = $246,046; 687 shares @ $329.82 = $226,586; total 1,433 shares for ~$472,632
• Footnote: The shares include 442 Dividend Equivalents (DEs) credited to unvested RSUs under Amgen’s equity plan and paid out in shares per the vesting schedule (F1)
• Transaction type code: F (payment of exercise price or tax liability / tax withholding via share surrender)
• Shares owned after the transaction: not specified in the provided filing excerpt
• Filing: Accession filed May 5, 2026 (reporting period May 2, 2026)

Context
This was a tax-withholding share surrender (often called a "sell to cover" or share-for-tax) tied to equity awards and dividend equivalents, not an open-market sale intended as market timing. Such transactions are common for executives when RSUs vest or dividend equivalents are paid and generally reflect tax settlement rather than a directional bet on the stock.